In my own sojourn with macular degeneration I have been treated by three different practices. Austin Clinical Research is the creme of the crop, period. Dr. Berger is amazingly skilled and surrounds himself with outstanding people. Valerie, Yong and Ivana stand out as caring exceptional professionals.
Retinal diseases vary widely, but most of them cause visual symptoms.
The eye contains millions of light-sensitive cells (rods and cones) and other nerve cells that receive and organize visual information. Your retina sends this information to your brain through your optic nerve, enabling you to see.
Treatment is available for some retinal diseases, but not all. By participating in a clinical trial, you are contributing to development of new and better treatments for the future. We strive to offer innovative treatment options that may be more effective, may slow or halt the disease process, prolong treatment intervals, and improve or maintain your vision.
By participating in the trial, I would receive the proper treatment for my BRVO. I would receive the existing drug which had been administered for BRVO for several years or a new drug which had shown positive results for similar eye problems. In addition, I felt I was participating in medical science throughout the trial.
Austin Clinical Research is currently enrolling patients with wet age-related macular degeneration and diabetic macular edema in studies evaluating a single administration of gene therapy treatment compared to standard of care. The goal with gene therapy is to greatly reduce or potentially eliminate the need for frequent eye injections. To learn more about these studies, please visit our enrolling trials page or contact us.
Over the past few years, our wonderful patients and staff contributed significant time and data, which has given rise to the approval of two new therapies for retinal diseases. Vabysmo, approved in January 2022 for wet AMD and diabetic macular edema, is the first ever bispecific antibody for use in the eye. Susvimo, approved in October of 2021 for wet AMD, is the first sustained delivery eye implant and alternative to eye injections. Both are produced by Genentech and clinical trial results showed that both treatments accomplished comparable visual acuity and disease stability results at less frequent treatment intervals compared to other FDA approved treatments.
Austin Clinical Research is now enrolling patients with dry eyes into clinical trials. If you have dry eyes and would like to be
considered for a clinical trial, please contact us. Next round of screening for the Palatin MELODY-1 dry eye study is open August 29, 2023 to August 30, 2023. Please contact our office to see if you might be a candidate and to schedule a screening visit.